Column Robustness Across 2000 Injections of a Small Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Orforglipron Formulation

Column Robustness Across 2000 Injections of a Small Molecule GLP-1 RA (Orforglipron) Formulation — Application Note Summary

Significance of the topic:

Preclinical formulations used in animal studies frequently contain high proportions of excipients (viscous cosolvents, buffers) that challenge chromatographic analysis and column lifetime. Reliable, high‑throughput QC methods are necessary to confirm dose concentration and stability throughout in vivo studies. Demonstrating chromatographic robustness against repeated injections of formulation matrix supports method suitability for routine preclinical analytics and reduces risk of study failure due to analytical variability or column failure.

Objectives and study overview:

This study aimed to develop a fast (5‑minute) reversed‑phase HPLC‑UV assay for an orforglipron formulation and to evaluate column and system robustness under intense use. The formulation was injected consecutively 2000 times while monitoring USP tailing factor, peak width (at 50% height), and system pressure at regular intervals to assess column fouling, stationary phase degradation, and method reproducibility.

Methodology and experimental design:

- Sample and formulation:

• Orforglipron formulated at 0.7 mg API/mL in a vehicle containing 10% polyethylene glycol 400, 10% propylene glycol, and 80% glycine buffer (100 mM glycine, 64 mM NaOH, pH 10).
• Aliquoted into sample vials and analyzed directly to represent realistic preclinical gavage matrices.

- Chromatographic method summary:

• Column: XBridge Premier BEH C8, 3.5 μm, 4.6 × 50 mm.
• System: Arc HPLC with Quaternary Solvent Manager, Flow‑Through‑Needle sample manager, and 2998 PDA detector; Empower CDS for data handling.
• Detection: UV at 254 nm.
• Mobile phases: A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile.
• Gradient: 40% B initial → linear to 100% B over 2 min → hold 1 min → return to 40% B over 1 min → re‑equilibrate 1 min; total run 5 min.
• Flow rate: 2.0 mL/min; column temperature: 50 °C; injection volume: 1 μL.
• System washes: 60:40 acetonitrile:water.

Instrumentation used (separate summary):

• Arc HPLC System with Quaternary Solvent Manager (QSM) and Flow‑Through‑Needle sample manager.
• 2998 Photodiode Array (PDA) Detector, monitoring at 254 nm.
• Column: Waters XBridge Premier BEH C8, 3.5 μm, 4.6 × 50 mm (p/n 186010950).
• Empower Chromatography Data System for acquisition and processing.

Main results and discussion:

- Specificity: Vehicle blank chromatogram showed no co‑eluting interferences at the API retention region, indicating method specificity for the intended assay.

- Peak shape and tailing: Over 2000 consecutive injections (monitoring performed every 10 injections), the USP tailing factor showed excellent stability. Percent change from previous measurements was typically <1% and the overall percent RSD was 0.80%, indicating negligible deterioration in peak symmetry or secondary interactions with the stationary phase.

- Peak width: Peak width measured at 50% height remained consistent across the dataset with changes from the initial value under 5% and overall percent RSD of 2.35%. This demonstrates maintained chromatographic efficiency despite exposure to viscous excipients and elevated operation temperature (50 °C).

- System pressure: The instrument recorded system pressures consistently below 2400 psi throughout the 2000 injections, well under the Arc HPLC maximum operating pressure of 9500 psi. The stable, relatively low pressure suggests limited column/system fouling and acceptable backpressure behavior when injecting viscous formulation matrices repeatedly.

- Visual chromatographic performance: Representative chromatograms at injection numbers 1, 500, 1000, 1500 and 2000 displayed consistent retention time, peak height, and shape, supporting method reproducibility and column durability.

Interpretation: The combination of robust BEH C8 stationary phase, short column geometry, high flow rate and a rapid gradient produced a high‑throughput method resilient to challenging formulation components. The data indicate that this configuration and operating conditions are suitable for long runs required in preclinical QC without frequent column replacement or extensive maintenance.

Benefits and practical applications of the method:

• Fast, 5‑minute run time enabling high sample throughput for formulation QC and stability checks in preclinical workflows.
• Demonstrated column resilience to viscous cosolvents and alkaline glycine buffer, reducing downtime and consumable costs for long preclinical campaigns.
• Sufficient specificity and chromatographic performance for dose confirmation in animal studies where UV detection is applicable.
• Approach suitable for routine monitoring of formulation integrity and for laboratories seeking rapid pass/fail QC of dosing solutions.

Limitations and practical considerations:

• Evaluation performed with a single stationary phase chemistry and column format; behavior may differ with other phases or longer columns.
• Detection was by UV at 254 nm; compounds lacking strong chromophores or co‑eluting impurities may require MS detection or orthogonal methods.
• Study did not report long‑term chemical degradation or stress testing of API; method addresses analytical robustness rather than stability‑indicating performance per se.
• Routine lab practice should consider sample filtration, periodic stronger column washes, or guard/pretreatment cartridges to further extend lifetime in very dirty matrices.

Future trends and potential extensions:

• Adoption of online sample cleanup (SPE) or automated dilution to handle highly viscous/formulated samples with minimal manual prep.
• Transition to UHPLC or core‑shell column technologies for even shorter cycle times and improved efficiency at lower solvent consumption.
• Integration with mass spectrometry for increased specificity and to monitor impurities or degradation products alongside potency.
• Development of predictive lifetime models for columns based on formulation composition, injection count, and pressure trends to optimize maintenance schedules.
• Exploration of greener mobile phases and solvent reduction strategies to lower environmental impact of high‑throughput preclinical testing.

Conclusion:

A 5‑minute reversed‑phase HPLC‑UV method using an XBridge Premier BEH C8 (3.5 μm, 4.6 × 50 mm) column demonstrated high specificity, reproducibility, and robustness for analysis of an orforglipron formulation under demanding conditions. Over 2000 consecutive injections, USP tailing factors and peak widths remained within tight tolerances (tailing RSD 0.80%, peak width RSD 2.35%), and system pressure stayed well below instrument limits (<2400 psi). These results support the method's suitability for high‑throughput QC of preclinical formulations and indicate the column/system were resistant to fouling under the tested conditions.

References:

1. Parasuraman S. Toxicological screening. J Pharmacol Pharmacother. 2011 Apr;2(2):74–79. doi:10.4103/0976-500X.81895. PMID:21772764; PMCID:PMC3127354.
2. Institutional Animal Care and Use Committee (IACUC) Policy for Dose Volumes in Laboratory Animals. Indiana University.
3. Tianwu X, Habib Z. Age‑Dependent Small‑Animal Internal Radiation Dosimetry. Mol Imaging. 2013;12:364–375. DOI:10.2310/7290.2013.00053.
4. Sloop KW, Willard FS, Cardona GR, Alsina‑Fernandez J, Vieth M, Cao J, Emmerson PJ. The Pharmacological Basis for Nonpeptide Agonism of the GLP‑1 Receptor by Orforglipron. Sci Transl Med. 2024;16(777):eadp5765.